Physician profile
Kartik Kalra
NPI 1437535283
$107,718.66
in general payments reported to CMS, 2019-2025
13 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $320 · 2023: $57.59 · 2024: $22K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Honoraria: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $12K · Food and Beverage: $3,419 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,966.66 |
| Honoraria | $33,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,698.00 |
| Travel and Lodging | $12,165.14 |
| Food and Beverage | $3,418.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $42,063.85 | 2024-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41,161.20 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $11,304.16 | 2024-2025 | |
| Travere Therapeutics, INC. | $10,411.97 | 2024-2025 | |
| Mozarc Medical US LLC | $1,244.71 | 2024 | Argyle |
| Vertex Pharmaceuticals Incorporated | $408.33 | 2025 | |
| Zoll Medical Corporation | $358.33 | 2025 | Defibrillator |
| Novartis Pharmaceuticals Corporation | $338.47 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $119.08 | 2022 | |
| Bard Peripheral Vascular, INC. | $116.22 | 2022 | |
| Nxstage Medical, INC. | $96.95 | 2023-2025 | Nxstage System One |
| Vantive US Healthcare LLC | $72.54 | 2025 | Renal - Pd |
| Genzyme Corporation | $22.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kartik Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.